Interleukin-23 Antagonists [MoA] - N0000192798

Pharmacologic Class Information

Pharmacologic Code N0000192798
Pharmacologic Name Interleukin-23 Antagonists
Pharmacologic Uses
  • interleukin-23 antagonist
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Interleukin-23 Antagonists

The following table contains 8 products whose active ingredient are classified under the same pharmacologic class Interleukin-23 Antagonists [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0074-1050Skyrizi Non-Proprietary Name: Risankizumab-rzaaInjectionSubcutaneousAbbvie Inc.ACTIVE
0074-2100Skyrizi Non-Proprietary Name: Risankizumab-rzaaInjectionSubcutaneousAbbvie Inc.ACTIVE
0074-5015Skyrizi Non-Proprietary Name: Risankizumab-rzaaInjectionIntravenousAbbvie Inc.ACTIVE
47335-177Ilumya Non-Proprietary Name: Tildrakizumab-asmnInjection, SolutionSubcutaneousSun Pharmaceutical Industries, Inc.ACTIVE
57894-054Stelara Non-Proprietary Name: UstekinumabSolutionIntravenousJanssen Biotech, Inc.ACTIVE
57894-060Stelara Non-Proprietary Name: UstekinumabInjection, SolutionSubcutaneousJanssen Biotech, Inc.ACTIVE
57894-061Stelara Non-Proprietary Name: UstekinumabInjection, SolutionSubcutaneousJanssen Biotech, Inc.ACTIVE
57894-640Tremfya Non-Proprietary Name: GuselkumabInjectionSubcutaneousJanssen Biotech, Inc.ACTIVE